(NASDAQ: OABI) Omniab's forecast annual revenue growth rate of 31.96% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.07%.
Omniab's revenue in 2026 is $28,939,000.On average, 9 Wall Street analysts forecast OABI's revenue for 2026 to be $4,124,614,845, with the lowest OABI revenue forecast at $3,617,790,709, and the highest OABI revenue forecast at $4,604,908,999. On average, 8 Wall Street analysts forecast OABI's revenue for 2027 to be $6,792,980,134, with the lowest OABI revenue forecast at $4,191,157,259, and the highest OABI revenue forecast at $11,889,636,122.
In 2028, OABI is forecast to generate $9,682,283,634 in revenue, with the lowest revenue forecast at $6,390,971,173 and the highest revenue forecast at $14,004,351,131.